SHV vs XBI

iShares Short Treasury Bond ETF vs SPDR S&P Biotech ETF

Quick take
  • • SHV has the lower expense ratio at 0.15% vs 0.35% for XBI.
  • • SHV pays a higher dividend yield (3.63%).

Side-by-side metrics

MetricSHVXBI
Expense ratio
Annual fee. Lower is better.
0.15%0.35%
Dividend yield
Trailing 12-month yield.
3.63%0.35%
AUM
Assets under management — bigger funds are typically more liquid.
$21.43B$10.92B
YTD return
3.04%28.80%
1-year return
——
3-year return
Annualized.
——
5-year return
Annualized.
——
10-year return
Annualized.
——
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
0.011.01
P/E ratio
——
Last price
$110.14$156.41
Inception
——
Issuer
iSharesState Street

SHV top holdings

Holdings data unavailable for SHV.

XBI top holdings

Top holdings · XBI
MRNAModerna Inc2.37%
NTRANatera Inc1.82%
HALOHalozyme Therapeutics Inc1.77%
TWSTTwist Bioscience Corp1.77%
BIIBBiogen Inc1.75%
AMGNAmgen Inc1.73%
EXELExelixis Inc1.73%
UTHRUnited Therapeutics Corp1.72%
ABBVAbbVie Inc1.71%
GILDGilead Sciences Inc1.70%
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%

About SHV

SHV (iShares Short Treasury Bond ETF) is US Treasuries maturing in under 1 year. Managed by iShares, the fund carries $21.4B in assets under management, an expense ratio of 0.15%, a dividend yield of 3.63%.

About XBI

XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.